Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017.
#ProstateCancer
#pcsm
castration-naïve prostate cancer
castration-resistant prostate cancer
cost and access to treatment
high-risk localized prostate cancer
low-middle income countries
oligometastatic prostate cancer
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
12
5
2019
medline:
19
5
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
To examine the results of the Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC) 2018, held for assessing the generalizability of consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC 2017) to Malaysia, a middle-income country. Six key sections were chosen: (1) high-risk localized and locally advanced prostate cancer, (2) oligometastatic prostate cancer, (3) castration-naïve prostate cancer, (4) castrate resistant prostate cancer, (5) use of osteoclast-targeted therapy and (6) global access to prostate cancer drugs. There were 101 consensus questions, consisting of 91 questions from APCCC 2017 and 10 new questions from MyAPCCC 2018, selected and modified by the steering committee; of which, 23 questions were assessed in both ideal world and real-world settings. A panel of 22 experts, comprising of 11 urologists and 11 oncologists, voted on 101 predefined questions anonymously. Final voting results were compared with the APCCC 2017 outcomes. Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic disease. No consensus was reached on using high-cost drugs in castration-naïve or castration-resistant metastatic prostate cancer in real-world settings. All panellists recommended using generic drugs when available. The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle-income country in a real-world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare.
Identifiants
pubmed: 31077523
doi: 10.1111/bju.14807
pmc: PMC6851975
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
373-382Informations de copyright
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.
Références
JAMA Oncol. 2016 Apr;2(4):493-9
pubmed: 26794729
JAMA. 2017 Jan 3;317(1):48-58
pubmed: 28030702
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Clin Cancer Res. 2013 Jul 1;19(13):3621-30
pubmed: 23649003
BJU Int. 2018 May;121 Suppl 3:22-27
pubmed: 29359883
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Ann Oncol. 2016 Jun;27(6):975-84
pubmed: 27052650
Lancet. 2011 Mar 5;377(9768):813-22
pubmed: 21353695
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Eur Urol. 2015 Jun;67(6):1028-1038
pubmed: 25301760
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
Lancet. 2011 Dec 17;378(9809):2104-11
pubmed: 22056152
Rev Urol. 2010 Spring;12(2-3):e86-96
pubmed: 20811557
Eur J Cancer. 2017 Mar;74:26-37
pubmed: 28335885
Clin Prostate Cancer. 2002 Dec;1(3):145-52
pubmed: 15046689
Urology. 2010 Sep;76(3):710-4
pubmed: 19931898
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Lancet Oncol. 2013 Feb;14(2):117-24
pubmed: 23294853
Nat Rev Urol. 2017 Jan;14(1):15-25
pubmed: 27725639
Lancet Oncol. 2014 Jun;15(7):738-46
pubmed: 24836273
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
Ann Oncol. 2018 May 1;29(5):1235-1248
pubmed: 29529169
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
BJU Int. 2005 Apr;95(6):751-6
pubmed: 15794776
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
J Clin Oncol. 2015 Jul 1;33(19):2143-50
pubmed: 25691677
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
BJU Int. 2019 Jan;123(1):22-34
pubmed: 30019467
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Lancet Oncol. 2013 Nov;14(12):e524-34
pubmed: 24176571
BJU Int. 2017 Nov;120 Suppl 3:35-42
pubmed: 28749017
J Clin Oncol. 2009 Apr 1;27(10):1564-71
pubmed: 19237632
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Ann Oncol. 2015 Aug;26(8):1589-604
pubmed: 26041764